What is the story about?
What's Happening?
Medtronic has received FDA approval for its Altaviva device, a neuromodulation therapy for urge urinary incontinence. The device is inserted near the ankle and sends electrical impulses to regulate bladder control. This approval marks a significant opportunity for Medtronic in the large market of overactive bladder treatment, offering a less invasive option compared to existing therapies.
Why It's Important?
The approval of the Altaviva device provides a new treatment option for millions of patients suffering from urge urinary incontinence, a condition that affects quality of life and poses economic burdens. Medtronic's device offers a less invasive alternative to sacral neuromodulation, potentially increasing patient acceptance and market growth. The device's long battery life and ease of use could make it a preferred choice among patients and healthcare providers.
What's Next?
Medtronic plans to capitalize on the large, underpenetrated market opportunity by accelerating sales at its pelvic health unit. The company is expected to make significant changes to its commercial organization to support the growth of this business. As the device becomes more widely available, Medtronic may see increased market share and further development of its neuromodulation portfolio.
AI Generated Content
Do you find this article useful?
